Have you ever dumped a bucket of ice water over your head? The sudden freeze is a shock to the system, causing shivers and ...

Trouble sleeping is common in other neurodegenerative diseases, but past research has only suggested that it occurs in ...

Individuals living with ALS are automatically eligible for Medicare when they start receiving Social Security benefits. Medicare should cover most diagnostics and treatments, but this depends on the ...

Neuropeutics Inc announces a collaboration with LifeArc to develop a new small molecule for the treatment of motor neuron disease (MND), also known as Amyotrophic Lateral Sclerosis (ALS).

A 22-month survival benefit was seen for a subset of ALS patients whose disease did not progress when treated with NP001 in ...

MNDs are neurological disorders that destroy motor neurons, the cells that control skeletal muscle activity such as walking, breathing, speaking, and swallowing.

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Neuvivo, a late-clinical stage biopharmaceutical company, today announced promising new results from a fresh analysis of a previous study of its investigational immunotherapy platform NP001 to treat ...

The Massachusetts based biotech will now press ahead with human trials for its antisense oligonucleotide (ASO) therapy, ...

Ahmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that the U.S. Food and Drug Administration ...

Zydus’ Usnoflast receives US FDA orphan drug designation to treat amyotrophic lateral sclerosis: Our Bureau, Mumbai Thursday, January 23, 2025, 12:15 Hrs [IST] Zydus, a leading, ...

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...